Product Information
KLOXXADO 8 MG NASAL SPRAY is a brand product labeled by Hikma Specialty USA Inc., priced at $59.7742 per EA under NDC 59467067901. Its NADAC has been published 233 times since Apr 20, 2022.
FDA first approved this application on Apr 29, 2021.
Strength
8 mg/.1mL
Manufacturer
Hikma Specialty USA Inc.NDC
59467067901
Classification
Brand
Dosage Form
SPRAY
Route
NASAL
Effective Date
9/23/2026
Active Ingredients
NALOXONE HYDROCHLORIDEApproval Type
New Drug (NDA)
FDA Application
NDA212045FDA Approved
4/29/2021
On Market Since
8/3/2021
Pharmacological Classes
Price Statistics
The NADAC for KLOXXADO 8 MG NASAL SPRAY has been published 233 times since Apr 20, 2022, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.
| Current price | $59.7742 per EA |
|---|---|
| All-time high | $60.2750 (Apr 10, 2024) |
| All-time low | $59.7104 (Jul 22, 2026) |
| 52-week high | $59.9502 |
| 52-week low | $59.7104 |
| Median price | $59.9584 |
| Average price | $59.9324 |
| Largest weekly change | +0.8% (Dec 20, 2023) |
| Weeks tracked | 233 |
| Tracking since | Apr 20, 2022 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Naloxone HCL market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Hikma Specialty USA Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Naloxone HCL market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Opioid Antagonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of KLOXXADO 8 MG NASAL SPRAY?
The current National Average Drug Acquisition Cost (NADAC) for KLOXXADO 8 MG NASAL SPRAY, manufactured by Hikma Specialty USA Inc., is $59.7742 per EA (NDC 59467067901), effective Sep 30, 2026.
How has the price of KLOXXADO 8 MG NASAL SPRAY changed over time?
Over the history we have for it, the NADAC for KLOXXADO 8 MG NASAL SPRAY has held within roughly two percent of its current level. It has been tracked across 233 weekly CMS publications since Apr 20, 2022.
What are the highest and lowest recorded NADAC prices for KLOXXADO 8 MG NASAL SPRAY?
Since Apr 20, 2022, the NADAC for KLOXXADO 8 MG NASAL SPRAY has ranged from a low of $59.7104 (Jul 22, 2026) to a high of $60.2750 (Apr 10, 2024), with a median of $59.9584 per EA.
Are there cheaper alternatives to KLOXXADO 8 MG NASAL SPRAY?
No other NADAC-published product currently shares the active ingredient and strength of KLOXXADO 8 MG NASAL SPRAY in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures KLOXXADO 8 MG NASAL SPRAY?
KLOXXADO 8 MG NASAL SPRAY (NDC 59467067901) is labeled by Hikma Specialty USA Inc., and CMS classifies it as a brand product.